Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Grows By 99.4%

Vincerx Pharma, Inc. (NASDAQ:VINC) was the target of a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 137,200 shares, an increase of 99.4% from the March 15th total of 68,800 shares. Based on an average daily volume of 1,040,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 3.1% of the company’s stock are short sold.

Vincerx Pharma Price Performance

Shares of VINC stock remained flat at $0.28 during trading hours on Friday. The company’s 50-day moving average price is $0.77 and its two-hundred day moving average price is $3.78. Vincerx Pharma has a 12 month low of $0.22 and a 12 month high of $19.88. The firm has a market cap of $1.44 million, a PE ratio of -0.01 and a beta of 1.67.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.